Researchers at the School of Public Health and Vanderbilt University School of Medicine received a $3.7 million grant from the National Institute on Drug Abuse to study buprenorphine dosing among pregnant women with opioid use disorder, as clinical guidelines remain inconsistent and state Medicaid policies often cap doses.
Following a December 2025 law intended to increase accessibility, it stands as the first medication for this disorder that can be distributed directly in doctor’s offices and pharmacies. Buprenorphine is among the three drugs approved by the US Food and Drug Administration for long-term treatment of opioid use disorder.
Fentanyl, which is up to 50 times stronger than heroin, continues to drive the opioid overdose epidemic across the nation. Pregnancy accelerates how the body metabolizes buprenorphine, meaning pregnant patients often require higher doses simply to avoid withdrawal symptoms. While a daily sublingual dose typically begins between 2 mg and 4 mg with a standard target of 16 mg to 24 mg, some individuals benefit from doses reaching 32 mg.
Researchers Secure NIH Grant For Dosing Study
Researchers at the School of Public Health and Vanderbilt University School of Medicine secured a five-year award from the National Institute on Drug Abuse to evaluate these clinical needs.
Many of these state programs cap daily medication dosages and sometimes discourage physicians from raising them during pregnancy.
Study Leaders Model Dosing Costs and Patient Outcomes
Collaborating with researchers from Boston Medical Center, the study leaders will assess national and state-level differences in dosing between pregnant and non-pregnant women. They will examine how prescribing practices have evolved in response to fentanyl use.
Investigators will utilize a decision analytic model to forecast results for pregnant and postpartum patients—including the financial impact of inadequate treatment or substandard care alongside maternal and infant mortality.
Hospital Tests Rapid Inpatient Micro-Induction
Researchers examined inpatient protocols at Cabell Huntington Hospital involving pregnant patients with opioid use disorder admitted between January 2020 and December 2021. Standard buprenorphine induction traditionally requires patients to reach a state of moderate withdrawal before taking the medication, a requirement that can prove distressing and prolong hospital stays.
Hospital staff implemented a rapid sublingual buprenorphine micro-induction protocol to mitigate these challenges. A retrospective cohort analysis of 98 patients compared this protocol against traditional induction approaches.
| Induction Strategy | Patient Readmission Rate |
|---|---|
| Rapid Micro-Induction Protocol | 20 percent |
| Traditional Induction Approach | 63.6 percent |
Readmission rates for substance use disorder during pregnancy dropped to 20 percent in the rapid induction group compared with 63.6 percent in the traditional induction cohort. The differences in both hospitalization duration and readmission rates demonstrated clinical utility for a population facing elevated health risks and treatment discontinuation, although the reduction in overall hospital length of stay did not reach statistical significance.